{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"88"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"371"},{"groupId":"OG001","value":"172"}],"units":"Participants"}],"description":"All-cause mortality is defined as all anticipated and unanticipated deaths due to any cause, with the number and frequency of such events by arm or comparison group of the clinical study.","groups":[{"description":"Participants with HER2-low, unresectable, and/or metastatic breast cancer who were previously treated with chemotherapy were randomized to receive an intravenous infusion of DS8201a (initial dose of 5.4 mg/kg) over approximately 90 minutes. If there was no infusion-related reaction (IRR), T-DXd doses after the initial dose of 5.4 mg/kg were infused over a minimum of 30 minutes.","id":"OG000","title":"Trastuzumab Deruxtecan (T-DXd)"},{"description":"Participants with HER2-low, unresectable, and/or metastatic breast cancer who were previously treated with chemotherapy and randomized to a physician's choice (capecitabine, eribulin, gemcitabine, paclitaxel, and nab-paclitaxel) in which the dose, regimen, administration, and dose modification followed the label approved in the country of drug administration or the National Comprehensive Cancer Network guidelines.","id":"OG001","title":"Physician's Choice"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All-cause mortality was assessed in the Safety Analysis Set.","reportingStatus":"POSTED","timeFrame":"From the date of randomization up to the date of death due to any cause, up to approximately 3 years","title":"All-Cause Mortality","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Participants"}